plasmod3..... I think macrea12 has tried to post a reseach...

plasmod3..... I think macrea12 has tried to post a reseach document on CXS by ABN AMRO. In fact, there are independent research reports by a number of other crowds out there, including Lodge Partners, and EG Capital.

The fact is that Novartis earns in the order of $US2.5 billion p.a from its CML treatment drug 'Gleevac'....big bickies.
CML occurances are growing every year. As you indicated, there are a number of mutations that patients can develop which adversely affects the effectiveness of this drug, of which the T315i is but one, and is the one that CXS's drug Ceflatonin seems to successfully treat - clinical testing underway now to confirm.


Now, the T315i mutation affects about 20% of CML patients, so we could assume that Ceflatonin may potentially earn revenues in time, in the order of 20% x US$2.5 b = US$500million X 50% (conservative factor) = $US250million.... is that reasonable ?...... if yes, that's not bad is it ?..... and that's to say nothing of the potential revenue streams from Qinamed and other drugs in the pipeline......... I think the market is re-rating CXS at the moment on the basis of these potential revenue streams. Ceflatonin is geting very close now I think, to having its effectiveness proven beyond any doubt..... you only have to look at all the positive independent scientific reports that CXS have announced over recent months.

Your thoughts Plasmod 3 ?